HuGE Literature Finder
Records 1-30
|
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
International journal of clinical oncology 2019 Mar 24 (3): 256-261. Negoro Yutaka, Yano Ryoichi, Yoshimura Mari, Suehiro Yoko, Yamashita Shinji, Kodawara Takaaki, Watanabe Kyohei, Tsukamoto Hitoshi, Nakamura Toshiaki, Kadowaki Maiko, Morikawa Miwa, Umeda Yukihiro, Anzai Masaki, Ishizuka Tamotsu, Goto Nobuyu |
|
[Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2018 Aug 40 (8): 594-599. Wang X F, Ma C, Gong F F, Yi S Y, Xing G C, Wang K J, Yang Q, Cao |
|
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
European journal of cancer (Oxford, England : 1990) 2018 Jun 99 66-77. Tejpar Sabine, Yan Pu, Piessevaux Hubert, Dietrich Daniel, Brauchli Peter, Klingbiel Dirk, Fiocca Roberto, Delorenzi Mauro, Bosman Fred, Roth Arnaud |
|
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Asia-Pacific journal of clinical oncology 2018 Jun . Yang Yuwei, Zhou MengMeng, Hu Mingjun, Cui Yanjie, Zhong Qi, Liang Ling, Huang F |
|
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
British journal of clinical pharmacology 2018 Mar . Riera P, Salazar J, Virgili A, Tobeña M, Sebio A, Gallano P, Barnadas A, Páez |
|
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
The pharmacogenomics journal 2018 01 18 (1): 35-42. Li M, Seiser E L, Baldwin R M, Ramirez J, Ratain M J, Innocenti F, Kroetz D |
|
Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Oncology letters 2017 Nov 14 (5): 5743-5752. Wang Yang, Yi Cuihua, Wang Yawei, Li Hui, Li Bei, Wang Dan, Du Jintong, Liu Lian, Wang Xiuw |
|
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
International journal of clinical oncology 2017 Oct 22 (5): 913-920. Ando Koji, Emi Yasunori, Suenaga Toyokuni, Hamanoue Masahiro, Maekawa Soichiro, Sakamoto Yasuo, Kai Seiichiro, Satake Hironaga, Shimose Takayuki, Shimokawa Mototsugu, Saeki Hiroshi, Oki Eiji, Sakai Kenji, Akagi Yoshito, Baba Hideo, Maehara Yoshihiko, |
|
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
Thoracic cancer 2017 Oct . Fukuda Minoru, Okumura Manabu, Iwakiri Tomomi, Arimori Kazuhiko, Honda Takuya, Kobayashi Kazuma, Senju Hiroaki, Takemoto Shinnosuke, Ikeda Takaya, Yamaguchi Hiroyuki, Nakatomi Katsumi, Matsuo Nobuko, Mukae Hiroshi, Ashizawa Kazu |
|
UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun . Zhang Xue, Yin Jia-Fu, Zhang Jiao, Kong Shu-Jia, Zhang Hong-Yin, Chen Xue-M |
|
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Thoracic cancer 2017 Jan 8 (1): 40-45. Fukuda Minoru, Shimada Midori, Kitazaki Takeshi, Nagashima Seiji, Hashiguchi Kohji, Ebi Noriyuki, Takayama Koichi, Nakanishi Yoichi, Semba Hiroshi, Harada Taishi, Seto Takashi, Okamoto Isamu, Ichinose Yukito, Sugio Ken |
|
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42. Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li |
|
Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).
Thoracic cancer 2016 Jul 7 (4): 467-72. Fukuda Minoru, Suetsugu Takayuki, Shimada Midori, Kitazaki Takeshi, Hashiguchi Kohji, Kishimoto Junji, Harada Taishi, Seto Takashi, Ebi Noriyuki, Takayama Koichi, Sugio Kenji, Semba Hiroshi, Nakanishi Yoichi, Ichinose Yuki |
|
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecaninduced toxicity in Chinese cancer patients.
International journal of clinical pharmacology and therapeutics 2016 Feb . Yan Liang, Wang Xiao-Fei, Wei Lu-Man, Nie Ya-Li, Liu Jing-Yang, Zhang Li-Ro |
|
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Drug metabolism and pharmacokinetics 2015 Dec . Atasilp Chalirmporn, Chansriwong Pichai, Sirachainan Ekapob, Reungwetwattana Thanyanan, Chamnanphon Montri, Puangpetch Apichaya, Wongwaisayawan Sansanee, Sukasem Chonlaph |
|
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
International journal of clinical oncology 2015 Dec . Miyata Yoshinori, Touyama Tetsuo, Kusumi Takaya, Morita Yoshitaka, Mizunuma Nobuyuki, Taniguchi Fumihiro, Manabe Mitsua |
|
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Pharmacogenetics and genomics 2015 Sep . Chen Sylvia, Villeneuve Lyne, Jonker Derek, Couture Félix, Laverdière Isabelle, Cecchin Erica, Innocenti Federico, Toffoli Giuseppe, Lévesque Eric, Guillemette Chant |
|
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Breast cancer (Tokyo, Japan) 2015 Jul 22 (4): 335-42. Otsuka Hiroko, Fujii Teruhiko, Toh Uhi, Iwakuma Nobutaka, Takahashi Ryuji, Mishima Mai, Takenaka Miki, Kakuma Tatsuyuki, Tanaka Maki, Shirouzu Kaz |
|
[Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Gan to kagaku ryoho. Cancer & chemotherapy 2015 May 42 (5): 585-9. Teruya Tsuyoshi, Nakachi Atsushi, Shimabukuro Nobuhiro, Toritsuka Daisuke, Azuma Yasuharu, Hanashiro Kiyotoshi, Nishiki Takehiro, Ota Morihito, Shimabuku Masamori, Shiroma Hiros |
|
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
The pharmacogenomics journal 2015 Mar . Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court M H, Innocenti F, Toffoli G, Lévesque E, Guillemette |
|
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2015 Jan 37 (1): 29-32. Ma Lixia, Chen Yan, Yang Changliang, Jiang Hui, Zhu Jing, Cheng Yi |
|
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Drug design, development and therapy 2015 9 3677-83. Yang Chen, Liu Ying, Xi Wen-qi, Zhou Chen-fei, Jiang Jin-ling, Ma Tao, Ye Zheng-bao, Zhang Jun, Zhu Zheng-ga |
|
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Journal of clinical pharmacology 2014 May 54 (5): 495-502. Suenaga Mitsukuni, Fuse Nozomu, Yamaguchi Tatsuro, Yamanaka Yasuhiro, Motomura Shigeki, Matsumoto Hiroshi, Hamamoto Yasuo, Mizunuma Nobuyuki, Doi Toshihiko, Hatake Kiyohiko, Iwasaki Junko, Ohtsu Atsus |
|
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Cancer chemotherapy and pharmacology 2014 Apr 73 (4): 779-88. Han Fei-fei, Guo Chang-long, Yu Dan, Zhu Jin, Gong Li-li, Li Guang-run, Lv Ya-li, Liu He, An Guang-yu, Liu Li-ho |
|
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
International journal of clinical oncology 2014 Apr 19 (2): 397-402. Hirose Kouichi, Yamashita Koushiro, Takada Hirofumi, Kaneda Noriko, Fukami Kohei, Maruo Eiji, Kitamura Mizuho, Hasegawa Junichi, Maeda Yorino |
|
The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2014 Feb 19 (1): 56-62. Chen Yi-Jing, Hu Fei, Li Chun-Yan, Fang Jue-Min, Chu Li, Zhang Xi, Xu Qi |
|
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Asian Pacific journal of cancer prevention : APJCP 2014 15 (7): 3335-41. Lu Yan-Yan, Huang Xin-En, Wu Xue-Yan, Cao Jie, Liu Jin, Wang Lin, Xiang J |
|
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Cancer science 2013 Dec 104 (12): 1662-9. Hazama Shoichi, Mishima Hideyuki, Tsunedomi Ryouichi, Okuyama Yusuke, Kato Takeshi, Takahashi Ken-ichi, Nozawa Hiroshi, Ando Hideaki, Kobayashi Michiya, Takemoto Hiroyoshi, Nagata Naoki, Kanekiyo Shinsuke, Inoue Yuka, Hamamoto Yoshihiko, Fujita Yusuke, Hinoda Yuji, Okayama Naoko, Oba Koji, Sakamoto Jun-ichi, Oka Masaa |
|
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
The Journal of pharmacology and experimental therapeutics 2013 Apr 345 (1): 95-101. Lévesque Eric, Bélanger Anne-Sophie, Harvey Mario, Couture Félix, Jonker Derek, Innocenti Federico, Cecchin Erica, Toffoli Giuseppe, Guillemette Chant |
|
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
The Tohoku journal of experimental medicine 2013 229 (2): 107-14. Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi |
|
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Medical oncology (Northwood, London, England) 2013 30 (3): 604. Gao Jing, Zhou Jun, Li Yanyan, Lu Ming, Jia Ru, Shen L |
|
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Pharmacogenomics 2012 Jun 13 (8): 889-99. Dias Mafalda M, McKinnon Ross A, Sorich Michael |
|
[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2012 132 (2): 231-6. Okazaki Keinosuke, Watanabe Toru, Saito Isao, Murayama Jun-Ichi |
|
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Zhonghua fu chan ke za zhi 2011 Dec 46 (12): 888-91. Li Hu, Huang He, Liu Ji-ho |
|
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Cancer 2011 Jul 117 (14): 3156-62. Shulman Katerina, Cohen Ilana, Barnett-Griness Ofra, Kuten Abraham, Gruber Stephen B, Lejbkowicz Flavio, Rennert G |
|
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Japanese journal of clinical oncology 2011 May 41 (5): 617-23. Ishida Hiroo, Fujita Ken-Ichi, Akiyama Yuko, Sunakawa Yu, Yamashita Keishi, Mizuno Keiko, Miwa Keisuke, Kawara Kaori, Ichikawa Wataru, Ando Yuichi, Saji Shigehira, Sasaki Yasutsu |
|
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
|
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Japanese journal of clinical oncology 2011 Apr 41 (4): 477-82. Okuyama Yusuke, Hazama Shoichi, Nozawa Hiroshi, Kobayashi Michiya, Takahashi Kenichi, Fujikawa Koshi, Kato Takeshi, Nagata Naoki, Kimura Humihiko, Oba Koji, Sakamoto Junichi, Mishima Hideyu |
|
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2011 Feb 131 (2): 239-46. Saito Yoshi |
|
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
The pharmacogenomics journal 2011 Feb 11 (1): 61-71. Glimelius B, Garmo H, Berglund A, Fredriksson L A, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius |
|
Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Jan 6 (1): 1. Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S |
|
Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Aug 16 (15): 3832-42. Hu Zhe-Yi, Yu Qi, Pei Qi, Guo Che |
|
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Jul 28 (20): 3227-33. McLeod Howard L, Sargent Daniel J, Marsh Sharon, Green Erin M, King Cristi R, Fuchs Charles S, Ramanathan Ramesh K, Williamson Stephen K, Findlay Brian P, Thibodeau Stephen N, Grothey Axel, Morton Roscoe F, Goldberg Richard |
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Cancer chemotherapy and pharmacology 2010 May 66 (1): 95-105. Sai Kimie, Saito Yoshiro, Maekawa Keiko, Kim Su-Ryang, Kaniwa Nahoko, Nishimaki-Mogami Tomoko, Sawada Jun-ichi, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Yamada Yasuhide, Tamura Tomohide, Yoshida Teruhiko, Matsumura Yasuhiro, Ohtsu Atsushi, Saijo Nagahiro, Minami Hirono |
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jun 27 (16): 2604-14. Innocenti Federico, Kroetz Deanna L, Schuetz Erin, Dolan M Eileen, Ramírez Jacqueline, Relling Mary, Chen Peixian, Das Soma, Rosner Gary L, Ratain Mark |
|
UGT1A1,A7 and A9 genotyping and pharmacokinetics of irinotecan-containing chemotherapy in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e14563. Valenzuela B, Nalda R, Duart M, Escudero V, Perez-Ruixo J, Martinez-Navarro E, Rebollo J, Gonzalez R, Brugarolas |
|
Use of genotype subset selections of multi-UGT1As polymorphisms to predict severe neutropenia and tumor responses of metastatic CRC patients received FOLFIRI regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e15038. Hazama S, Okuyama Y, Kato T, Okayama N, Hinoda Y, Sakamoto J, Mishima H, Fujita Y, Hamamoto Y, Oka |
|
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
International journal of clinical oncology 2009 Apr 14 (2): 136-42. Onoue Masahide, Terada Tomohiro, Kobayashi Masahiko, Katsura Toshiya, Matsumoto Shigemi, Yanagihara Kazuhiro, Nishimura Takafumi, Kanai Masashi, Teramukai Satoshi, Shimizu Akira, Fukushima Masanori, Inui Ken-ic |
|
UGT1A1 Haplotype Mutation among Asians in Singapore.
Neonatology 2009 Mar 96 (3): 3. Zhou YY, Lee LY, Ng SY, Hia CP, Low KT, Chong YS, Goh DL |
|
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
Clinical pharmacology and therapeutics 2009 Feb 85 (2): 149-54. Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, Takeda Y, Isobe H, Ogura T, Yokoyama A, Watanabe |
|
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Cancer chemotherapy and pharmacology 2008 Nov 62 (6): 1075-83. Font Albert, Salazar Ramon, Maurel Joan, Taron Miquel, Ramirez Jose Luis, Tabernero Josep, Gallego Rosa, Casado Esther, Manzano Jose Luis, Carcereny Enric, Guix Marta, Fernández-Llamazares Jaume, Rosell Rafa |
|
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
British journal of cancer 2008 Jul 99 (2): 275-82. Kweekel D M, Gelderblom H, Van der Straaten T, Antonini N F, Punt C J A, Guchelaar H-J, |
|
Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008 Mar 17 (3): 695-701. Lankisch Tim O, Schulz Christoph, Zwingers Thomas, Erichsen Thomas J, Manns Michael P, Heinemann Volker, Strassburg Christian |
|
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Cancer science 2007 Sep 98 (9): 1461-7. Jada Srinivasa Rao, Lim Robert, Wong Chiung Ing, Shu Xiaochen, Lee Soo Chin, Zhou Qingyu, Goh Boon Cher, Chowbay Balr |
|
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Clinical colorectal cancer 2007 Jul 6 (8): 583-7. Fakih Marwan G, Ross Mary Ellen, Starostik Pe |
|
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Journal of clinical pharmacology 2007 Jan 47 (1): 78-86. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV |
|
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Cancer 2006 Mar 106 (5): 1007-16. Massacesi Cristian, Terrazzino Salvatore, Marcucci Fabiana, Rocchi Marco B, Lippe Paolo, Bisonni Renato, Lombardo Marco, Pilone Alberta, Mattioli Rodolfo, Leon Alber |
|
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (4): 1504-11. Soepenberg Otto, Dumez Herlinde, Verweij Jaap, de Jong Floris A, de Jonge Maja J A, Thomas José, Eskens Ferry A L M, van Schaik Ron H N, Selleslach Johan, Ter Steeg Judith, Lefebvre Patricia, Assadourian Sylvie, Sanderink Ger-Jan, Sparreboom Alex, van Oosterom Allan |
|
Clinical pharmacogenetics of irinotecan (CPT-11).
Drug metabolism reviews 2005 37 (3): 565-74. Ando Yuichi, Hasegawa Yoshino |
|
Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jul 22 (14_suppl): 3053. Rao R D, Reid J M, Goetz M P, Furth A F, Mandrekar S J, Adjei A A, Ames M M, Safgren S L, Erlichman C, Pitot H |
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Apr 22 (8): 1382-8. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ |
|
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Cancer research 2000 Dec 60 (24): 6921-6. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa |
- Page last reviewed:Mar 16, 2019
- Page last updated:Sep 18, 2020
- Content source: